Eisai Innovation, Inc. and MBC BioLabs are pleased to announce Qinotto, Inc. as the winner of the Eisai 2022 Golden Ticket Competition.

Eisai Innovation, Inc. selected Qinotto as the winner of the 2022 Golden Ticket Competition. Qinotto will receive free lab space for one year in MBC BioLabs’ state-of-the-art laboratory facility in San Carlos, California, enabling Qinotto to pursue drug discovery and innovation for the potential future benefit of patients worldwide.

Entries were received across a broad range of disease areas and included a number of exciting, innovative technologies. Qinotto was selected based on their proprietary platform technology that can identify novel genetic regulators of the blood brain barrier (BBB), which enables brain delivery of large molecule CNS therapeutics and the treatment of diseases with underlying BBB dysfunction.